L. Almeida

发表

Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects

A. Falcão, Manuel Vaz da Silva, Raquel Costa, 2009, Fundamental & clinical pharmacology.

Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.

P. Soares-da-Silva, J. Rocha, Raquel Costa, 2013, Clinical therapeutics.

Psychomotor Effects of Mexazolam vs Placebo in Healthy Volunteers

L. Almeida, M. Vaz-da-Silva, Pedro Silveira, 2002 .

Cardiac safety profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor in non-human primates, human young and elderly healthy volunteers and hypertensive patients

A. Falcão, P. Soares-da-Silva, P. Lacroix, 2015 .

Safety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine-β-Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy Subjects

A. Falcão, P. Soares-da-Silva, J. Rocha, 2010, Drugs in R&D.

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers.

A. Falcão, P. Soares-da-Silva, J. Rocha, 2009, Molecular nutrition & food research.

Mexazolam and Alprazolam in the Treatment of Generalised Anxiety Disorder

M. Figueira, R. Albuquerque, L. Almeida, 2001 .

Effect of opicapone multiple‐dose regimens on levodopa pharmacokinetics

A. Falcão, P. Soares-da-Silva, N. Fauchoux, 2017, British journal of clinical pharmacology.

Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.

P. Soares-da-Silva, M. Bonifácio, L. Almeida, 2007, CNS drug reviews.

Pharmacokinetic–Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/Carbidopa

A. Falcão, P. Soares-da-Silva, J. Maia, 2004, Clinical neuropharmacology.

Pharmacokinetics and Pharmacodynamics of BIA 3-202, a Novel COMT Inhibitor, during First Administration to Humans

P. Soares-da-Silva, L. Almeida, 2003, Drugs in R&D.

Pharmacokinetic–pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide

A. Falcão, P. Soares-da-Silva, J. Maia, 2003, European Journal of Clinical Pharmacology.

Pharmacokinetic and Pharmacodynamic Profiles of BIA 3–202, a Novel Catechol‐O‐Methyltransferase (COMT) Inhibitor, during Multiple‐Dose Administration to Healthy Subjects

P. Soares-da-Silva, L. Almeida, 2003, Journal of clinical pharmacology.

Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.

A. Falcão, P. Soares-da-Silva, M. Bonifácio, 2013, British journal of clinical pharmacology.

Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects

A. Falcão, P. Soares-da-Silva, M. Bonifácio, 2013, Clinical Pharmacokinetics.

Pharmacokinetic-Pharmacodynamic Interaction between Nebicapone, a Novel Catechol-O-Methyltransferase Inhibitor, and Controlled-Release Levodopa/Carbidopa 200 mg/50 mg

A. Falcão, P. Soares-da-Silva, J. Rocha, 2008, Drugs in R&D.

Eslicarbazepine Acetate: A Double‐blind, Add‐on, Placebo‐controlled Exploratory Trial in Adult Patients with Partial‐onset Seizures

C. Elger, J. Cramer, M. Bialer, 2007, Epilepsia.

Safety, Tolerability and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic Agent, during First Administration to Humans

P. Soares-da-Silva, L. Almeida, 2003, Drugs in R&D.

Single‐Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Etamicastat (BIA 5–453), a New Dopamine β‐Hydroxylase Inhibitor, in Healthy Subjects

A. Falcão, P. Soares-da-Silva, M. Bonifácio, 2012, Journal of clinical pharmacology.

Bioavailability and Bioequivalence of Two Enteric-Coated Formulations of Omeprazole in Fasting and Fed Conditions

A. Falcão, P. Soares-da-Silva, J. Maia, 2005, Clinical drug investigation.

Eslicarbazepine acetate (BIA 2-093)

P. Soares-da-Silva, L. Almeida, 2011, Neurotherapeutics.

Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers

E. Sellers, D. Milovan, P. Soares-da-Silva, 2010, Epilepsy & Behavior.

Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.

A. Falcão, P. Soares-da-Silva, E. Soares, 2010, Clinical therapeutics.

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures

A. Gil-Nagel, P. Soares-da-Silva, J. Maia, 2009, Acta neurologica Scandinavica.

Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate.

A. Falcão, P. Soares-da-Silva, E. Soares, 2008, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment

P. Soares-da-Silva, J. Maia, L. Almeida, 2008, European Journal of Clinical Pharmacology.

Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2‐093), a new voltage‐gated sodium channel blocker

A. Falcão, P. Soares-da-Silva, D. Mazur, 2007, Biopharmaceutics & drug disposition.

Single‐Dose and Steady‐State Pharmacokinetics of Eslicarbazepine Acetate (BIA 2–093) in Healthy Elderly and Young Subjects

A. Falcão, P. Soares-da-Silva, D. Mazur, 2005, Journal of clinical pharmacology.

Effect of Food on the Pharmacokinetic Profile of Eslicarbazepine Acetate (BIA 2-093)

A. Falcão, P. Soares-da-Silva, J. Maia, 2005, Drugs in R&D.

Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I.

H. Grunze, A. Falcão, P. Soares-da-Silva, 2015, Journal of affective disorders.

Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women

A. Falcão, P. Soares-da-Silva, H. Gama, 2013, Epilepsy Research.

Effect of food on the pharmacokinetic profile of trans-resveratrol.

A. Falcão, P. Soares-da-Silva, J. Rocha, 2008, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics of Trans‐resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects

A. Falcão, P. Soares-da-Silva, J. Rocha, 2009, Journal of clinical pharmacology.

Safety, Tolerability, and Pharmacokinetic Profile of BIA 2‐093, a Novel Putative Antiepileptic, in a Rising Multiple‐Dose Study in Young Healthy Humans

P. Soares-da-Silva, L. Almeida, 2004, Journal of clinical pharmacology.

Bioequivalence of Final Tablet Formulation and Research Tablet Formulation of Eslicarbazepine Acetate in Healthy Volunteers

P. Soares-da-Silva, R. Cerdeira, L. Almeida, 2009 .

Eslicarbazepine Acetate (BIA 2-093)

C. Fontes-Ribeiro, A. Falcão, P. Soares-da-Silva, 2005 .

Personality characteristics of volunteers in Phase 1 studies and likelihood of reporting adverse events.

A. Falcão, A. Albino-Teixeira, L. Almeida, 2008, International journal of clinical pharmacology and therapeutics.

Intramuscular Etofenamate versus Diclofenac in the Relief of Renal Colic

A. Fraga, L. Almeida, Pedro Silveira, 2003, Clinical drug investigation.

Interpersonal Values of Healthy Subjects Who Volunteer for Phase I Clinical Trials

A. Albino-Teixeira, P. Soares-da-Silva, L. Almeida, 2009, Pharmaceutical Medicine.

Adverse non-drug-related complaints by healthy volunteers in Phase I studies compared to the healthy general population.

A. Albino-Teixeira, L. Almeida, R. Coelho, 2008, International journal of clinical pharmacology and therapeutics.

Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events

T. Kashdan, A. Albino-Teixeira, P. Soares-da-Silva, 2008, European Journal of Clinical Pharmacology.

Healthy subjects volunteering for Phase I studies: influence of curiosity, exploratory tendencies and perceived self-efficacy.

A Albino-Teixeira, T. Kashdan, A. Albino-Teixeira, 2008, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers

C. Elger, M. Bialer, A. Falcão, 2013, Epilepsia.

Steady‐state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers

A. Falcão, P. Soares-da-Silva, J. Rocha, 2013, Epilepsia.

Pharmacokinetics, Efficacy, and Tolerability of Eslicarbazepine Acetate in Children and Adolescents With Epilepsy

A. Falcão, P. Soares-da-Silva, L. Almeida, 2008, Journal of clinical pharmacology.

Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453)

A. Falcão, J. Rocha, L. Almeida, 2011, Drugs in R&D.

Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.

A. Falcão, P. Soares-da-Silva, J. Rocha, 2011, Clinical therapeutics.

Why healthy subjects volunteer for phase I studies and how they perceive their participation?

Patrício Soares-da-Silva, P. Soares-da-Silva, Luis Almeida, 2007, European Journal of Clinical Pharmacology.

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study

C. Elger, P. Soares-da-Silva, P. Halász, 2009, Epilepsia.

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy

E. Ben-Menachem, A. Hufnagel, P. Soares-da-Silva, 2010, Epilepsy Research.

Effects of enalapril and imidapril in the capsaicin cough challenge test and spirometry parameters in healthy volunteers

H. Gama, J. Maia, L. Almeida, 2004 .

Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures

C. Elger, E. Perucca, A. Falcão, 2011, Epilepsy Research.

Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: Results of a 1-year open-label extension study

E. Ben-Menachem, A. Hufnagel, A. Falcão, 2013, Epilepsy Research.

Effect of 3 Single‐Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol‐O‐Methyltransferase Activity and Motor Response in Patients With Parkinson Disease

J. Ferreira, A. Falcão, P. Soares-da-Silva, 2016, Clinical pharmacology in drug development.

A Double‐Blind, Randomized, Placebo and Active‐Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease

W. Poewe, O. Rascol, C. Sampaio, 2010, CNS neuroscience & therapeutics.

Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease

C. Sampaio, J. Ferreira, M. Coelho, 2008, Clinical neuropharmacology.

The Role of Socioeconomic Conditions and Psychological Factors in the Willingness to Volunteer for Phase I Studies

A. Falcão, A. Albino-Teixeira, P. Soares-da-Silva, 2008, Pharmaceutical Medicine.

Long‐term efficacy and safety of eslicarbazepine acetate: Results of a 1‐year open‐label extension study in partial‐onset seizures in adults with epilepsy

C. Elger, J. Cramer, A. Guekht, 2010, Epilepsia.

Efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Integrated analysis of pooled data from double‐blind phase III clinical studies

C. Elger, E. Ben-Menachem, A. Gil-Nagel, 2013, Epilepsia.

Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects

A. Falcão, P. Soares-da-Silva, J. Rocha, 2010, Acta neurologica Scandinavica.

Dosage Form Proportionality and Food Effect of the Final Tablet Formulation of Eslicarbazepine Acetate

C. Fontes-Ribeiro, A. Falcão, P. Soares-da-Silva, 2008, Drugs in R&D.

Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor

A. Falcão, P. Soares-da-Silva, J. Maia, 2010, Current medical research and opinion.

Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation

P. Soares-da-Silva, M. Bonifácio, L. Almeida, 2006, Drug Metabolism and Disposition.

Pharmacokinetics, Drug Interactions and Exposure-Response Relationship of Eslicarbazepine Acetate in Adult Patients with Partial-Onset Seizures

A. Falcão, P. Soares-da-Silva, E. Fuseau, 2012, CNS Drugs.

Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects

A. Falcão, P. Soares-da-Silva, J. Rocha, 2010, Current medical research and opinion.

Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.

A. Falcão, P. Soares-da-Silva, J. Rocha, 2009, Clinical Therapeutics.

Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study

P. Soares-da-Silva, M. Gutierrez, J. Litwin, 2012, Journal of clinical pharmacology.

Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects.

C. Fontes-Ribeiro, A. Falcão, P. Soares-da-Silva, 2009, International journal of clinical pharmacology and therapeutics.

Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.

A. Falcão, P. Soares-da-Silva, E. Soares, 2010, Clinical therapeutics.